A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

NCT07197554 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Ewing Sarcoma
Hepatocellular Carcinoma (HCC)
Biliary Tract Cancer (BTC)

Interventions

DRUG: ST-01156

Sponsor

SEED Therapeutics, Inc.